BNGO

Bionano Genomics, Inc. is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).

Wall Street analysts forecast BNGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNGO is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Bionano Genomics Inc revenue for the last quarter amounts to 7.37M USD, increased 21.31 % YoY.

Bionano Genomics Inc. EPS for the last quarter amounts to -1.59 USD, decreased -94.86 % YoY.

Bionano Genomics Inc (BNGO) has 98 emplpoyees as of December 16 2025.

Today BNGO has the market capitalization of 15.67M USD.